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The E6 oncoproteins of high-risk human papillomaviruses provide important functions not only for malignant transformation but also in the
productive viral life cycle. E6 proteins have been shown to bind to a number of cellular factors, but only a limited number of analyses have
investigated the effects of these interactions on the viral life cycle. In this study, we investigated the consequences of HPV 31 E6 binding to
E6TP1, a putative Rap1 GAP protein. HPV 16 E6 has been shown to bind as well as induce the rapid turnover of E6TP1, and similar effects were
observed with HPV 31 E6. Mutation of amino acid 128 in HPV 31 E6 was found to abrogate the ability to bind and degrade E6TP1 but did not
alter binding to another α-helical domain protein, E6AP. When HPV 31 genomes containing mutations at amino acid 128 were transfected into
human keratinocytes, the viral DNAs were not stably maintained as episomes indicating the importance of this residue for pathogenesis. Many E6
binding partners including E6TP1 are cytoplasmic proteins, but E6 has been also reported to be localized to the nucleus. We therefore investigated
the importance of E6 localization to the nucleus in the viral life cycle. Using a fusion of E6 to Green Fluorescent Protein, we mapped one
component of the nuclear localization sequences to residues 121 to 124 of HPV 31 E6. Mutation of these residues in the context of the HPV 31
genome abrogated the ability for episomes to be stably maintained and impaired the ability to extend the life span of cells. These studies identify
two activities of HPV 31 E6 that are important for its function in the viral life cycle and for extension of cell life span.
© 2006 Elsevier Inc. All rights reserved.Keywords: Viral life cycle; HPV; Nuclear localization; E6TP1Introduction
Human papillomaviruses (HPVs) are small DNAviruses that
contain double-stranded circular genomes of approximately
8000 base pairs in size. HPVinfection is causally associated with
the development of various hyperproliferative diseases of the
epithelia (Howley and Lowy, 2001). In particular, infection by
the high-risk HPVs types such as HPV 16, 18, 31, and 54 is the
single most important risk factor for the development of the
cervical cancers (Laimins, 1993; Lowy et al., 1994; zur Hausen,
2002; zur Hausen and de Villiers, 1994). This association with
malignancy is dependent on the action of the two viral
oncoproteins, E6 and E7. The E6 protein mediates the turnover⁎ Corresponding author. Fax: +1 312 503 0649.
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doi:10.1016/j.virol.2006.08.028of the tumor suppressor protein p53 (Huibregtse et al., 1991;
Scheffner et al., 1990, 1993; Werness et al., 1990), while E7
binds and inactivates the retinoblastoma (pRb) family of proteins
(Cheng et al., 1995; Dyson et al., 1989; Martin et al., 1998;
Munger et al., 1989). In addition, several studies have identified
p53- and pRb-independent activities of E6 and E7, which are
also important for HPV-induced oncogenesis (Brehm et al.,
1999; Kiyono et al., 1998; Klingelhutz et al., 1996; Liu et al.,
1999).
The life cycle of HPV is closely linked to the differentiation
program of the host keratinocyte (Howley and Lowy, 2001).
HPVs infect keratinoctyes in the basal layer that become
exposed following microtraumas to the epithelia. Following
entry, viral genomes are established as episomes and replicate
together with the host DNA through the action of cellular
replication proteins working with the viral factors, E1 and E2
(Stubenrauch and Laimins, 1999). Following cell division, one
of the infected daughter cells migrates away from the basal layer
and undergoes differentiation. Upon initiating differentiation,
Fig. 1. Diagram of a linearized HPV 31 genome identifying the viral open
reading frames and the two major viral promoters (P97 and P742). Schematic
depicting the amino acid residues of HPV31 E6 important for binding to the
E6TP1 and its nuclear accumulation. The two E6 mutant genomes were
examined in this study; E6I128T contains a substitution of the 128th isoleucine
with threonine while E6NLS4A contains a substitution of three lysines and
arginine from amino acid 121 to 124 with four alanines.
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cells continue to cycle through the action of the E7 protein
(Cheng et al., 1995; Flores et al., 1999; Halbert et al., 1992). In
highly differentiated suprabasal cells, late viral functions are
activated including the amplification of viral genomes and the
expression of the late viral proteins (Cheng et al., 1995; Flores
et al., 1999; Halbert et al., 1992; Hummel et al., 1992). The E6
protein plays an important role in the viral life cycle by
contributing to the stable maintenance of viral episomes in
undifferentiated cells (Thomas et al., 1999) and may mediate
additional effects in differentiated suprabasal cells.
Recent studies have demonstrated that the binding of E6 to
cellular proteins other than p53 is important for viral
pathogenesis. The binding of HPV 31 E6 to PDZ proteins
through a motif present at its C-terminus was shown to be
important for mediating early viral functions in undifferentiated
cells (Lee and Laimins, 2004). A number of additional E6-
interacting proteins have been identified that contain a seven
amino acid motif which forms part of an α-helical structure (Be
et al., 2001; Chen et al., 1998). One of these α-helical domain-
containing proteins is E6AP, an E3 ubiquitin ligase necessary
for E6-mediated degradation of p53 (Huibregtse et al., 1991;
Scheffner et al., 1990, 1993; Werness et al., 1990). Other α-
helical domain-containing proteins that have been shown to
bind to E6 include E6BP (Chen et al., 1995), a calcium-binding
protein of the CREC family, and E6TP1 (Gao et al., 1999), a
putative Rap1 GTPase activating protein (GAP).
Studies have shown that the ability of HPV 16 E6 to
immortalize human mammary epithelial cells correlated with its
ability to bind and degrade E6TP1 (Gao et al., 1999; Gardiol et
al., 1999). Furthermore, transgenic mice expressing an HPV 16
E6 mutant defective for binding to E6AP and E6BP exhibited a
reduced oncogenic potential in vivo (Nguyen et al., 2002). In
contrast, another study reported that mutants of E6 which
exhibited reduced binding to E6AP and E6BP were still able to
induce the immortalization of mammary epithelial cells (Liu et
al., 1999). It is unclear if all high-risk types HPV E6 proteins
bind these α-helical domain-containing proteins and what the
physiological significance of these interactions is to HPV life
cycle.
The high-risk E6 proteins are localized to both the cytoplasm
and the nucleus. E6TP1, E6AP, and E6BP are all found in the
cytoplasm, while the PDZ-domain-containing proteins are
detected at cytoplasmic membranes. Additional binding
partners of E6 have been identified that are nuclear in location.
These include transcriptional regulators such as c-Myc (Gross-
Mesilaty et al., 1998), ADA3 (Kumar et al., 2002), CBP/p300
(Patel et al., 1999), IRF-3 (Ronco et al., 1998), MCM7
(Kukimoto et al., 1998), and DNA repair proteins such as
XRCC-1 (Iftner et al., 2002), and O(6)-MGDMT (Srivenugopal
and Ali-Osman, 2002). This suggests that nuclear localization
of E6 may be required for some function in the viral life cycle.
While it has been reported that HPV 16 E6 contains a complex
nuclear localization signal (NLS) consisting of three distinct
domains (Tao et al., 2003), another study indicated that one of
these motifs alone was sufficient for nuclear localization
(Le Roux and Moroianu, 2003). In the present study, we haveexamined two different functions of HPV 31 E6 in the viral life
cycle. We determined that HPV 31 E6-mediated degradation of
E6TP1 is important for the stable maintenance of viral episomes
and the extension of cell life span. In addition, we mapped one
component of the nuclear localization signal of HPV 31 E6 and
demonstrated that this sequence was important for E6's function
in the viral life cycle.
Results
A threonine substitution at the isoleucine 128 of HPV 31 E6
inhibits the E6-mediated degradation of E6TP1
In order to begin to investigate the functions of E6 that are
important for its role in the viral life cycle, we have utilized
genetic analyses in the context of complete viral genomes. The
first step in such studies is the identification of mutations in E6
that interfere with binding of cellular factors or other activities.
With this goal in mind, we focused on HPV 31 E6 interactions
with the α-helical domain protein, E6TP1, which is a putative
Rap1 GAP protein. It was previously demonstrated that
mutation of the isoleucine at amino acid 128 in HPV 16 E6
abrogated its ability to bind proteins that contain α-helical
domains (Liu et al., 1999). This amino acid is conserved in HPV
31 E6, and we investigated the effects of mutating this residue
on interactions with E6TP1 (Fig. 1). For these studies, we used
transient transfection of myc-tagged E6TP1 expression vectors
together with plasmids encoding either wild-type HPV 31 E6 or
a mutant E6 encoding a threonine at position 128 instead of an
isoleucine (I128T). At 48 h after transfection, total protein
lysates were prepared and analyzed by Western blot analysis
using an antibody to myc. As shown in Fig. 2A, two bands were
detected by Western analysis using extracts from cells
transfected with expression vectors for myc-tagged E6TP1
(quantified in Fig. 2B). The slowest migrating band corresponds
Fig. 2. (A) Western blot analysis of myc-tagged E6TP1 proteins in the presence
of HPV 31 E6 wild-type or E6I128T proteins in C33A cells. Myc-tagged E6TP1
expression vectors were transfected either alone or together with increasing
amount of HPV 31 E6 wild-type as well as HPV 31 E6I128T expression vectors
into C33A cells. At 48 h after transfection, equivalent amounts of whole-cell
extracts from each of the transfected cells were isolated and separated on an
SDS-polyacrylamide gel and transferred to membrane. This membrane was
probed with anti-myc antibody, and proteins were visualized by chemilumines-
cence. Lane 1: control; lane 2: 1 μg of myc-E6TP1 plasmid; lane 3: 1 μg of myc-
E6TP1 plasmid+1 μg of HPV 31 E6; lane 4: 1 μg of myc-E6TP1+2 μg of
HPV 31 E6 plasmids; lane 5: 1 μg of myc-E6-TP1+1 μg of HPV 31 E6 I128T
plasmid; lane 6: 1 μg of myc-E6TP1+2 μg of HPV 31 E6 I128T plasmids.
Total DNAwas normalized to 3 μg per transfection. (B) Quantification of data
in panel A.
Fig. 3. (A) Western blot analysis of HA-tagged E6AP proteins in the presence of
HPV 31 E6 wild-type or E6I128T proteins in C33A cells. HA-tagged E6AP
expression vectors were transfected either alone or together with increasing
amount of HPV 31 E6 wild-type as well as HPV 31 E6I128Texpression vectors.
At 48 h after transfection, equivalent amounts of whole-cell extracts were
subjected to Western blot analysis using anti-HA antibody. A graph providing
quantitation of the data is shown. (B) GST pull-down assay examining the
interaction of HPV 31 E6 and E6I128Twith E6AP. GST and GST-E6AP fusion
proteins conjugated with the glutathione–agarose beads were mixed with in-
vitro translated HPV 31 E6 and E6I128T proteins radiolabeled with [35S]
cysteine. Bound proteins were eluted and separated on an SDS-polyacrylamide
gel for autoradiography. Quantitation of the data relative to E6TP1 binding to
wild-type E6 (set to 100) is indicated below lanes.
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corresponds to the endogenous myc protein. In the untrans-
fected control lane, only the faster migrating band was seen
(lane 1). When an myc-tagged E6TP1 vector was cotransfected
with an equal amount of HPV 31 E6 expression vector, we
observed an approximate 40% reduction in levels of the tagged
protein (lane 3). As the amount of cotransfected HPV 31 E6
expression plasmid was increased two-fold, we observed a 90%
decrease in the levels of tagged E6TP1 (lane 4). When equal
amounts of the tagged E6TP1 expression construct were
cotransfected with HPV31 E6 plasmid in which amino acid
128 was altered to threonine, no decrease in the levels of E6TP1
was seen (lane 5). However, cotransfection of higher amounts of
HPV 31 E6I128T plasmids with tagged E6TP1 expression
vectors resulted in an approximate 30% reduction in levels of
the tagged protein (lane 6). This suggests that mutation of amino
acid 128 significantly impairs the ability of HPV31 E6 to
degrade E6TP1.
For HPV 16 E6, mutation of amino acid 128 has been
reported to block binding to E6AP and thus prevent its
degradation (Liu et al., 1999). We investigated whether similareffects were seen with the HPV 31 E6 protein and used an HA-
tagged E6AP expression vector that has been used previously
for the HPV 16 studies (Gardiol et al., 1999). When HPV 31 E6
expression vectors were cotransfected with plasmids expressing
HA-E6AP into cells, reduced levels of tagged E6AP were seen
by Western analysis as compared to those detected in
transfections with HA-E6AP vector alone (Fig. 3A). Interest-
ingly, when we cotransfected the HPV 31 I128T E6 and HA-
E6AP vectors, we observed a similar reduction in levels as seen
in cotransfections with HPV 31 E6 (Fig. 3A). This experiment
was repeated twice with similar results. We conclude that
introduction of the I128T mutation into HPV 31 E6 does not
alter its ability to degrade to E6AP. We next investigated the
ability of HPV 31 E6 and E6I128T to bind E6AP. For this
purpose, we used in-vitro translated HPV 31 E6 and E6I128T
Table 1
Comparison of maximum passage numbers of the HFKs transfected with the
neomycin resistance gene only or together with either HPV 31 wild-type or one
of two mutant genomes (E6I128T and E6NLS4A) after a drug selection
Cell line A B C
Neo control 3 2 1
HPV31 >20 >20 >20
E6I128T 3 2 2
E6NLS4A 5 4 4
Three different HFKs isolates used for the stable transfection were referred to as
A, B, and C, respectively.
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down assays. In previous studies with HPV 16 E6, E6AP
binding was shown to be dependent upon amino acid 128,
however, in our study, no differences were detected in the
binding of E6AP to wild-type or mutant HPV 31 E6 proteins
(Fig. 3B). We conclude that, while HPV 31 E6 binds and
induces the degradation of E6AP, it does not depend on amino
acid 128 for this activity. Similarly, E6BP has also been shown
to bind HPV 16 E6 and that alteration of amino acid 128 of E6
abrogates its ability to bind to E6BP (Liu et al., 1999). When we
performed pull-down experiments with GST-HPV 31 E6 in the
presence of cell extracts, no association with E6BP was
observed (data not shown).
It was next important to demonstrate that the introduction of
threonine in place of isoleucine did not change the half life of
HPV 31 E6. We are not able to immunoprecipitate HPV 31 E6
proteins from cells using antibodies or to observe these proteins
in Western analyses, and so we have relied on the use of tagged
proteins. For these studies, we have used tagged HPV 31 E6
with Green Fluorescent Protein (GFP). Vectors expressing GFP-
tagged HPV 31 E6 wild-type and GFP-tagged E6I128T mutant
proteins were transfected into cells. At 48 h after transfection,
cell lysates were examined for E6 levels in Western analyses
using a GFP antibody. As seen in Fig. 4, no significant
differences were seen in the levels of wild-type or E6I128T
proteins. We performed similar determinations of half life using
an HA-tagged HPV18 E6 vector and found that the 128
mutation had no effect on stability (data not shown). For
technical reasons that are unclear, we were not able to express
HA-tagged HPV 31 E6 proteins.
HPV 31 E6I128T mutant genomes do not extend cell life span
and fail to stably maintain episomes
We next investigated the effects of introducing the I128T
mutation in the context of the complete HPV 31 genome on the
ability to extend the life span of transfected human keratino-
cytes. It has been shown that, when HPV 31 genomes are
recircularized and transfected into keratinocytes, HPV-positive
cells exhibit extended life spans and become immortal (Frattini
et al., 1996). For the current analysis, we recircularized both
wild-type and E6I128T mutant genomes and transfected them
into normal human keratinocytes along with a neomycin drugFig. 4. Western blot analysis of cell lysates of 293-T cells transiently transfected
with HPV 31 E6 GFP fusion plasmids: pSG5-GFP-WTE6, pSG5-GFP-
WTE6I128T and pSG5-GFP-E6NLS4A. Whole-cell lysates were harvested at
48 h post-transfection and subjected to Western blot analysis using an anti-GFP
antibody. Corresponding proteins are indicated: HPV31 wild-type E6, I128T
mutant E6, or NLS mutant E6.resistance marker. Following drug selection, colonies were
pooled and passaged. As shown in Table 1, cells transfected
with HPV 31 E6I128T mutant genomes or drug resistance
marker alone senesced after a few passages in culture, while
cells containing wild-type HPV 31 could be passaged greater
than 20 times. These experiments were repeated three times
with independently transfected host keratinocytes derived from
different donors and observed similar results. We conclude that
mutation of amino acid 128 of HPV 31 E6 impairs the ability of
the viral genome to extend the life spans of the transfected cells.
It was also important to examine the state of viral DNA in
these transfected cells prior to senescence. Total DNA was
isolated from keratinocytes transfected with wild-type and
E6I128T mutant genomes at passage two following selection
(greater than 17 cell doublings) and examined by Southern blot
analysis for the state of viral DNA. As shown in Fig. 5A, only
wild-type HPV 31 genomes were stably maintained as
episomes. In cells transfected with E6I128T mutant genomes,
the viral DNA was found to be integrated at very low copy
numbers. Similar results were seen in three independent
transfections (data not shown). We conclude that amino acid
128 of HPV 31 E6 is important for the stable maintenance of the
HPV31 viral genomes.
As a control, we sought to confirm that the alteration of
amino acid 128 did not result in a cis mutation that altered
stability of transcripts encoding the replication proteins E1 and
E2, which could indirectly lead to loss of replication ability.
Previous studies demonstrated that transcripts encoding E1 and
E2 initiate at the early promoter and include sequences in the E6
open reading frame (Hubert and Laimins, 2002). While
genomes containing stop codons in E6 were shown to have
little effect on transient replication, mutation of the E6 splice
donor resulted in reduced expression of E1 leading to impaired
replication (Hubert and Laimins, 2002; Thomas et al., 1999).
We used this same assay to investigate if the E6I128T mutation
exerts a cis effect that was responsible for reduced ability to
stably replicate genomes. As shown in Fig. 5B, at 5 days after
transfection into SCC-13 cells, the mutant genomes were able to
replicate at levels comparable or even slightly higher than the
wild-type genome. This indicates that the E6I128T mutation
does not result in a cis defect in the replication ability of the
HPV 31 genome. Overall, our studies indicate that the
introduction of the I128T mutation into HPV 31 genomes
significantly impairs the ability of viral DNA to be stably
maintained as episomes and to extend the life span of cells.
Fig. 5. (A) Southern blot analysis of HFKs stably transfected with HPV 31 wild-
type, E6I128T, and E6NLS4A genomes following selection and expansion in
monolayer cultures. First and second lanes contain 500 pg and 25 pg of
linearized HPV 31 genome as copy number control, respectively. Next, four
lanes contain 10 μg of uncut total DNA isolated from cells transfected with a
neomycin gene only or together with HPV 31 wild-type and two mutant
genomes. The multimeric as well as the episomal forms of the viral genomes are
indicated at the left side of the autoradiograph. A broad band of low intensity is
present in the lanes containing DNA isolated from cells transfected with mutant
genomes. Viral copy numbers in the cells with integrated genomes are
significantly reduced from that seen in cells containing wild-type genomes. (B)
Southern blot analysis of SCC-13 cells transiently transfected with HPV 31
wild-type, E6I128T, and E6NLS4A genomes as well as an untransfected control.
First and second lanes contain 100 pg and 25 pg of linearized HPV 31 genome as
copy number control, respectively.
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dependent upon amino acids 121–124
Previously we demonstrated that the binding of E6 to the
PDZ domain proteins, which are localized at cytoplasmic
membranes, provides an important activity in the HPV 31 life
cycle (Lee and Laimins, 2004). In the present study, we
observed that the interaction of HPV 31 E6 with the
cytoplasmic protein E6TP1 also plays an important role.
However, E6 has been reported to localize to both the cytoplasm
as well as the nucleus (Grossman et al., 1989; Kanda et al.,
1991; Sherman and Schlegel, 1996). We therefore wanted to
investigate if the activities of E6 in the nucleus were necessary
for some aspect of the viral life cycle. In studies examining HPV
16 E6, it was shown that amino acids 121–124 (KKQR) are
important for its nuclear localization (Fig. 1B) though thecomplete signal may actually be a multicomponent element.
Sequence comparison of HPV 31 and 16 E6 proteins identified
a similar domain of positively charged amino acids in the HPV
31 E6 protein (121–124 KKKR). We investigated if these
residues were important for HPV 31 E6 localization to the
nucleus by constructing a fusion of E6 with Green Fluorescent
Protein (GFP) coding sequences inserted in frame at the N-
terminus (GFP-31E6). In addition, a mutant GFP-31E6
expression vector was constructed in which amino acids 121–
124 were changed to four alanines (GFP-31E6NLS4A).
Plasmids expressing GFP alone, GFP 31E6, and GFP
31E6NLS4A were transfected into cells, and the subcellular
localization of the GFP-fused proteins was examined by
fluorescence microscopy. As shown in Figs. 6A and B, ex-
pression of GFP by itself resulted in a uniform distribution
throughout the cell, while the GFP 31E6 protein was found to
localize largely to the nucleus with a minor population in the
cytoplasm (Figs. 6C and D). This is in agreement with
published data on the localization of HPV 16 and 18 E6
proteins (Kanda et al., 1991; Sherman and Schlegel, 1996). In
cells transfected with the GFP 31E6NLS4A construct, a
uniform distribution of signal was observed throughout the
cell and this was markedly different from what was observed
with the GFP 31E6 protein (Figs. 6E and F). Mutation of the
KKKR motif HPV 31 E6 reduced the amount accumulated in
the nucleus resulting in a fairly uniform distribution throughout
the cell. We conclude that the residues 121–124 in HPV 31 E6
are important for nuclear localization, though additional
sequences may also be required.
In order to investigate if mutation of amino acids 121–
124 altered protein stability, we performed similar experi-
ments to those already described for the I128T mutant of E6.
In this analysis, expression vectors for GFP 31E6 and GFP
31E6NLS4A were transiently transfected into cells. At 48 h
post-transfection, cell lysates were prepared and the levels of
GFP-tagged E6 were examined by Western blot analysis using
an antibody to GFP. As shown in Fig. 4, no significant
differences in amount of E6 wild-type and mutant proteins
were detected. This suggests that mutating the charged amino
acids at amino acids 121–124 does not alter the stability of E6.
Amino acids 121–124 of HPV 31 E6 are important for
extended life span and stable replication of the viral genomes
We next examined if alteration of HPV 31 E6 nuclear
localization affected aspects of the viral life cycle. For these
studies, we introduced the aa 121–124 mutation into E6 in the
context of the complete HPV 31 genome. The recircularized
wild-type and mutant genomes were then transfected into
normal human keratinocytes along with a drug selectable marker
as described in Materials and methods. Pooled drug-resistant
cells were isolated and examined for the ability to be passaged
for extended periods of time. Cells containing genomes with the
121–124 mutation senesced after several passages (Table 1).
When we examined the state of viral DNA in the cells containing
121–124 mutant genomes at early passage, the genomes were
found to be integrated at low copy numbers (Fig. 5A). These
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transfected cell lines, and similar results were observed. Finally,
we confirmed that the 121–124 mutation in E6 does not exert a
cis effect on E1/E2 gene expression by performing transient
transfection assay as described previously. As shown in Fig. 5B,
no effect of the mutation was observed in the short-term
replication assay demonstrating that the 121–124 mutation does
not have a cis effect on replication. Overall, our studies indicate
that localization of E6 to the nucleus is important for several
aspects of the HPV life cycle such as extension of cell life span
and stable maintenance of viral episomes.Fig. 6. Subcellular localization of GFP in pSG5-GFP (A, B), pSG5-GFP-WTE6 (C, D
were obtained using an inverted fluorescence microscope and deconvolved for highe
images B, D, and F show the merged GFP and DAPI fluorescence.Discussion
In the present study, we investigated the importance of HPV
31 E6 induced degradation of the α-helical domain-containing
protein E6TP1 on the viral life cycle. Previous studies suggested
that high-risk E6 proteins may associate with the α-helical
domain-containing proteins, such as E6TP1, E6BP and E6AP,
through similar sequences (Be et al., 2001; Chen et al., 1998).
Our studies indicate that differences exist between HPV 16 E6
and HPV 31 E6 in these properties, and this has allowed us to
examine the contribution of HPV 31 E6 interactions with), and pSG5-GFP-E6NLS4A (E, F) in 293-T cells, 24 h post-transfection. Images
r image quality. Images A, C, and E are shown with GFP fluorescence only, and
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binding and degradation of E6TP1 by HPV 31 E6 are required
to extend the life span of human keratinocytes as well as for the
long-term, stable replication of the viral genome. These two
properties may be inter-related such that the enhanced
proliferation of keratinocytes may be necessary to facilitate
maintenance of episomes as senescing cells seem to quickly
lose this ability. In addition, normal cells do not tolerate the
long-term presence of extrachromosomal DNA and E6 proteins
may target the corresponding surveillance mechanisms to allow
for maintenance of HPV episomes. E6-mediated degradation of
E6TP1 may play a direct or indirect role in overcoming these
surveillance mechanisms to allow for the maintenance of HPV
episomes.
Our studies also indicate that HPV 31 E6, like HPV 16 E6,
binds to E6AP and mediates its auto-degradation. However, the
interaction domain is not the same as that for E6TP1. While
previous studies had suggested that degradation of E6TP1
occurred through E6AP (Gao et al., 2002), our studies indicate
that E6AP binding alone is not sufficient for this activity and
that other factors are probably involved. Whether E6AP plays
any role in HPV 31 E6-mediated degradation of E6TP1 or
contributes to E6's role in the viral life cycle is not clear at this
time. A previous study by Park and Androphy demonstrated
that degradation of p53 was necessary for maintenance of HPV
16/31 chimeric genomes while E6AP binding alone was not
(Park and Androphy, 2002). A second α-helical domain-
containing protein, E6BP, that was shown to be a binding
partner of HPV 16 E6 was found not to bind to HPV 31 E6.
Therefore, our studies suggest that all high-risk E6 proteins do
not bind to the α-helical domain-containing proteins in a similar
manner. Overall, our studies indicate that degradation of E6TP1
by E6 is important in the HPV 31 life cycle.
The E6TP1 protein is expressed in many cell types and
contains a GAP domain that selectively interacts with Ras-
related small G proteins called Raps. HPV 16 E6 has been
shown to inhibit the GAP function of Rap1 and 2, resulting in
enhanced GTP loading of Rap (Singh et al., 2003). Expression
of Rap1 has also been shown to revert the transformed
phenotype of viral K-ras-transformed NIH3T3 cells (Kitayama
et al., 1989). Furthermore, Rap1 binds to Raf-1 as well as the
catalytic subunit of phosphotidylinositol 3-kinase and so
antagonizes Ras function (Frech et al., 1990; Hata et al.,
1990; Herrmann et al., 1996). E6-mediated degradation of
E6TP1 may lead to increased cell proliferation through
inhibition of GAP activity of E6TP1 toward Rap proteins, and
this is likely to be important for HPV pathogenesis. It will be
interesting to see what effect blocking E6TP1 function in
normal keratinocytes by siRNA treatment has on cell prolifera-
tion and whether this can complement E7 function in inducing
cell immortalization. It is possible that E6TP1 and p53
degradation are two important properties mediated specifically
by high-risk HPVs E6 protein to allow for viral replication.
Many of the factors that have been shown to bind E6 are
localized to the cytoplasm and plasmamembranes. However, our
studies indicate that E6 also has activities in the nucleus that are
important forviralpathogenesis.We identifieda regionof4aminoacids (121–124) that is important for HPV 31 E6 nuclear
localization. Although mutation of this putative NLS of HPV31
E6 did not completely block the nuclear localization, it
significantly impaired this activity. A tri-partite NLS (NLS1, 2,
and 3) has been reported for HPV 16 E6, and mutation of at least
two different NLSs was reported to be necessary to completely
exclude E6 from the nucleus (Tao et al., 2003). In our studies,
mutation of oneNLS element at amino acids 121–124 inHPV31
E6 (corresponding to NLS3 in HPV 16 E6) resulted in a uniform
distribution of HPV 31 E6 throughout the cytoplasm and nucleus
(Taoetal.,2003). It ispossiblethatadditionalsequencesinHPV31
E6 besides NLS3 may be required to completely exclude
localization to the nucleus, but in our study mutation of this one
element was sufficient to impair E6 function. Finally, we cannot
exclude the possibility that an uncharacterized factor binds to
amino acids 121–124 in HPV 31 E6 and that this activity is also
important for E6's role in the viral life cycle. A number of nuclear
proteins have been identified as binding partners for E6, and these
are involved in a variety of cellular processes such as transcrip-
tional control (c-Myc,ADA3,CBP/p300, IRF-3),DNAsynthesis
(MCM7), and DNA repair (XRCC-1 and O (6)-MGDMT). It is
unlikely that E6TP1 binding is affected by this mutation as its
interaction site is located outside the nuclear localization signal.
Furthermore, E6TP1 is a cytoplasmic protein.Overall,we believe
that binding of E6 to one or more nuclear factors provides an
important activity mediated by E6 in the viral life cycle.
Materials and methods
Cell culture
Human foreskin keratinocytes (HFKs) were isolated from
neonatal foreskin circumcisions and grown in serum-free
keratinocyte growth medium (Clonetics, San Diego, CA) as
previously described (Halbert et al., 1992). The untransfected
and HPV 31-transfected HFKs were maintained with mitomy-
cin-treated NIH3T3 fibroblast feeders in E-medium (Bedell et
al., 1989). E-medium also contains 5% fetal bovine serum and
was supplemented with mouse epidermal growth factor
(Collaborative Biomedical Products, Bedford, MA) to a final
concentration of 5 ng/ml. Prior to harvesting for DNA and
protein isolation, NIH3T3 fibroblast feeders were removed with
0.5 mM EDTA in phosphate-buffered saline. SCC-13 cells were
maintained in E-medium with fibroblast feeders while 293-T
and C33A cells were grown in Dulbecco's Modified Eagle
Medium supplemented with 10% fetal bovine serum.
Plasmids
pBR322-HPV31 contains the complete HPV 31 genome
sequence inserted into the EcoRI site of pBR322. The nucleotide
sequence ATA that corresponds to amino acid 128 (isoleucine)
was changed to ACC (threonine) through the use of Quick-
Change™XL site-directed mutagenesis kit (Stratagene, La Jolla,
CA) as described by the manufacturer and confirmed by
sequencing. The nucleotide sequence AAA-AAG-AAA-CGA
(amino acids 121–124) was changed to GCA-GCG-GCA-GCA,
208 C. Lee et al. / Virology 358 (2007) 201–210which encodes four consecutive alanines by the same Quick-
Change™XL method. The resultant pBR322-HPV31 plasmids
containing thedesiredmutationswere thendigestedwithSpeI and
BanII restriction enzymes to release the 1.2 kb DNA fragment
encompassing the entire E6 sequence. These 1.2 kb DNA
fragments were then inserted in place of the SpeI–BanII fragment
ofE6inplasmidcontainingacompletewild-typeHPV31.This re-
cloning ensured that there were no second site mutations
elsewhere in the genomes that could have been generated by the
PCR reaction. The 1.2 kb SpeI–BanII fragment region of the
resultant plasmid was then sequenced to confirm the presence of
the desired E6 substitutions. pcDNA3.1(−)31E6 and pcDNA3.1
(−)31E6I128T were constructed by inserting PCR fragments
containing thewild-typeHPV31E6 and E6I128Tsequences into
the EcoRI and HindIII restriction sites of pcDNA3.1(−) vector.
pSG5-GFP was constructed by insertion of GFP with PCR
generatedEcoRI restriction sites into the pSG5 vector.Wild-type
pSG5-GFP-WTE6 was constructed by inserting E6 with
PCR generated BamHI restriction sites into the pSG5-GFP
construct. The plasmids pSG5-GFP31E6NLS4A and pSG5-
GFP31E6I128T were then generated by using Quick-
Change™XL site-directed mutagenesis kit (Stratagene, La
Jolla, CA) as described by the manufacturer and confirmed by
sequencing. pSG5 and pcDNA3.1(−) vectorswere obtained from
Stratagene (Stratagene, La Jolla, CA) and Invitrogen (Invitrogen,
Carlsbad, CA), respectively. Expression vectors for HA-tagged
E6AP(Kaoet al., 2000),GST-E6AP(Huibregtse et al., 1993), and
myc-taggedE6TP1(Singhetal.,2003)weredescribedpreviously.
Generation of stable cell lines
Ten micrograms of pBR322-HPV31 plasmid DNA was
digested with EcoRI to release the HPV31 DNA sequence. The
restriction enzyme was heat-inactivated by incubation at 65 °C
for 15 min, and the released viral genome was religated with
800 U of T4 DNA ligase at 15 °C overnight. The religated DNA
was then precipitated with isopropyl alcohol and washed with
70% ethanol. The DNA pellet was then resuspended in 10 mM
Tris–1 mM EDTA (pH 7.5) and used for transfection. HFKs
were grown in 6 cm culture dish to 50–60% confluency in
serum-free keratinocyte growth medium (Clonetics, San Diego,
CA). One microgram of religated HPV31 genomes was
cotransfected with 1 μg of pSV2neo plasmids into HFKs using
Fugene (Roche Diagnostics, Mannheim, Germany) transfection
reagents as described by the manufacturer. Transfected HFKs
were transferred onto mitomycin-treated feeders the following
day. Drug selection with G418 (Gibco BRL) started 2 days after
transfection according to the following schedules: 200 μg/ml of
G418 for 4 days and 100 μg/ml of G418 for 3 days. Drug-
resistant colonies were pooled and expanded for analysis.
In-vitro transcription and translation and GST pull-down assay
Rabbit reticulocyte lysate system was used to in-vitro
transcribe and translate pSG5-31E6 and pSG5-31E6I128T
vectors to produce the HPV 31 E6 and E6I128T proteins
radiolabelled with [35S] cysteine (Promega, Madison, WI). Thepurification of the GST and GST-E6AP fusion proteins was
performed as previously described (Lee and Laimins, 2004).
Comparable amounts of each [35S] cysteine-labeled E6
protein were incubated with 2 μg of the GST and GST-
E6AP fusion protein coupled on glutathione–agarose beads in
250 μl of binding buffer (100 mM NaCl, 100 mM Tris–HCl
[pH 8.0], 1% Nonidet P-40 [NP-40], 2 mM DTT, 1 mM
phenylmethylsulfonyl fluoride). The mixtures were subjected
to shaking at 4 °C for 3 h, and the beads were washed four
times with 1 ml of the binding buffer for each wash. The
proteins associated with the beads were then released and
subjected to SDS–12% polyacrylamide gel electrophoresis.
The gels were dried and visualized with autoradiography.
Southern blot analysis
For the transient replication assays, recircularized HPV 31
genomes were transfected into SCC-13 cells and DNA isolated
as described previously (Hubert et al., 1999). For the stable
replication assay, total genomic DNA was prepared by phenol-
chloroform extraction and analyzed by Southern analysis as
previously described (Fehrmann et al., 2003).
Transient transfections
For GFP analyses, 293-T cells or C33A cells seeded at
approximately 30% confluency in 10 cm dishes were transiently
transfected with 6 mg of pSG5-GFP, pSG5-GFP-WTE6, or
pSG5-GFP-E6NLS4A using Fugene6 transfection reagents
(Roche Diagnostics, Mannheim, Germany). For studies with
myc-E6TP1, the myc-tagged E6TP1 expression construct was
transfected alone or together with high-risk wild-type and
mutant E6 plasmids into C33A cells seeded at approximately
50% confluence in 10 cm dishes using Fugene6 transfection
reagents (Roche Diagnostics, Manheim, Germany). The total
amount of transfected DNAwasmaintained constant. After 48 h,
cells were harvested and lysates used in Western blot analysis.
Western blot analysis
Whole-cell extracts were prepared in RIPA buffer containing
a cocktail of protease inhibitors (Complete, Mini; Roche Diag-
nostic), and total protein was quantitated with the Bradford
assay (Bio-Rad). Equal amounts of protein were electro-
phoresed on an SDS-polyacrylamide gel, subsequently trans-
ferred to a polyvinylidene difluoride membrane (Immobilon-P;
Millipore, Bedford, MA) and probed with the following primary
antibodies as previously described (Fehrmann et al., 2003): anti-
HA (12CA5; Boehringer Mannheim), anti-GFP (JL-8; Clon-
tech, Mountain View, CA), and anti-myc (9E10; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). Proteins were visualized
via enhanced chemiluminescence (Amersham Pharmacia).
Fluorescence microscopy
293-T cells were seeded on BD BioCoat collagen I coated
coverslips (BD Biosciences, Bedford, MA) and transiently
209C. Lee et al. / Virology 358 (2007) 201–210transfected using Fugene6 transfection reagent (Roche Diag-
nostics, Mannheim, Germany) at 30% confluency in 6-well
plates. After 24 h, the coverslips were rinsed twice with
phosphate buffered saline (Invitrogen, Carlsbad, CA) and fixed
for 30 min in 4% paraformaldehyde. Cells were rinsed,
permeabilized with 1% Triton-X for 5 min on ice and then
rinsed with PBS. Cells were then stained with DAPI for 5 min,
rinsed again with PBS and mounted on slides. Images were
captured in z-series by a Leica DM IRE2 inverted fluorescence
microscope system and processed using Openlab software and
deconvolved using Volocity software (Improvision, Lexington,
MA).
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